Growth Metrics

Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2016 - 2025)

Jazz Pharmaceuticals has reported Free Cash Flow over the past 16 years, most recently at -$453.5 million for Q4 2025.

  • Quarterly Free Cash Flow fell 207.12% to -$453.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $497.7 million through Dec 2025, down 64.34% year-over-year, with the annual reading at $497.7 million for FY2025, 64.34% down from the prior year.
  • Free Cash Flow was -$453.5 million for Q4 2025 at Jazz Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Over five years, Free Cash Flow peaked at $1.3 billion in Q3 2025 and troughed at -$755.3 million in Q2 2025.
  • The 5-year median for Free Cash Flow is $290.9 million (2022), against an average of $247.8 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 742.36% in 2022 and later plummeted 332.93% in 2025.
  • Tracing JAZZ's Free Cash Flow over 5 years: stood at $167.8 million in 2021, then soared by 98.22% to $332.6 million in 2022, then tumbled by 52.72% to $157.2 million in 2023, then surged by 169.25% to $423.4 million in 2024, then crashed by 207.12% to -$453.5 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$453.5 million, $1.3 billion, and -$755.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.